Neurocrine Biosciences, Inc.(NASDAQ: NBIX) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA(valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and data analyses from a Phase III study on opicapone, an investigational treatment for Parkinson’s disease.
These results will be presented at the 2018 World Congress on Parkinson’s Disease and Related Disorders (IAPRD) in Lyon, France, Aug. 19-22, 2018.
‘Neurocrine Biosciences is committed to bringing innovative and effective treatments to patients living with movement disorders,’ said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. ‘We look forward to providing additional analyses of INGREZZA’s long-term efficacy in tardive dyskinesia, as well as findings from the Phase III BIPARK-I study of opicapone in Parkinson’s disease. We believe these results will help healthcare providers further understand the benefits of INGREZZA and the potential of opicapone to help patients suffering from these serious, and often isolating, movement disorders.’
Highlighted poster presentations on INGREZZA include data from two long-term studies examining the treatment’s safety and efficacy over 48 weeks in patients with tardive dyskinesia, including patient-reported outcome results from the Phase III KINECT 4 study and an open-label, rollover trial reporting on symptom improvement and patient satisfaction with treatment.
Neurocrine will also present three analyses on opicapone from the Phase III BIPARK-I study highlighting the efficacy and safety of once-daily opicapone treatment in patients with Parkinson’s disease, compared to placebo and entacapone. Primary outcomes from the BIPARK-I study were previously published in Lancet Neurology, with the outcomes from the open-label extension phase of the BIPARK-I study subsequently published in Neurology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.